Invitation to presentation of Recipharm’s interim report

Recipharm will publish its interim report for January-March 2014 on May 8 at
07:45 CET. The company invites investors, analysts and media to a conference
call with a web presentation (in English) on May 8 at 10:00 CET, where CEO
Thomas Eldered and CFO Björn Westberg will present and comment on the interim
report and answer questions.
The report will be available on Recipharm’s website www.recipharm.com from 07:45
CET the same day.

To participate in the teleconference, please dial:

From Sweden, tel: +46 8-506 443 86
From the UK, tel: +44 20 7153 9154
From Denmark, tel: +45 32 71 42 62
From Finland, tel: +358 9 8171 0375

Pin code for participants: 610969#

To access the presentation during the conference, please use the following link:
http://event.onlineseminarsolutions.com/r.htm?e=790519&s=1&k=14C38F170510E2C72A5
0 
78973AF57A6C

To access the presentation afterwards, please use the following link:
http://event.onlineseminarsolutions.com/r.htm?e=790519&s=1&k=14C38F170510E2C72A5
0 
78973AF57A6C

For more information, please contact:
Björn Westberg, CFO
Tel: +46 8 602 46 20; e-mail: bjorn.westberg@recipharm.com

For questions about participation at the event, please contact:
Linda Holmström, Brand & Communications Manager
Tel: +46 70 873 40 95; e-mail: linda.holmstrom@recipharm.com
About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry based in Sweden employing some
1,500 employees. Recipharm offers manufacturing services of pharmaceuticals in
various dosage forms, production of clinical trial material and pharmaceutical
product development. Recipharm currently manufactures more than 200 different
products to both Big Pharma and smaller research- and development companies.
Recipharm’s turnover is approximately SEK 2.1 billion and the Company operates
development and manufacturing facilities in Sweden, France, the UK, Germany and
Spain and is headquartered in Jordbro.
Invitation to presentation of Recipharm’s interim report for the first quarter of 2014 on May 8
